Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | SREBF2 | Q12772 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20390901 | 0.83 | CYP19A1 (0.47) | SMN1; SMN2RAB9ANPC1SREBF2KDM4E | |
| SCHEMBL13622940 | 0.81 | RAB9A (0.58) | SMN1; SMN2RAB9ANPC1SREBF2KDM4E | |
| SCHEMBL9831216 | 0.80 | GFER (0.58) | SMN1; SMN2RAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL20390377 | 0.80 | GFER (0.37) | SMN1; SMN2RAB9ANPC1SREBF2KDM4E | |
| SCHEMBL20390848 | 0.80 | GFER (0.37) | SMN1; SMN2RAB9ANPC1SREBF2KDM4E | |
| SCHEMBL13145486 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2RAB9ANPC1SREBF2KDM4E | |
| SCHEMBL9830768 | 0.79 | NPC1 (0.53) | SMN1; SMN2RAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL9830921 | 0.79 | RAB9A (0.53) | SMN1; SMN2RAB9ANPC1SREBF2KDM4E | |
| SCHEMBL9830040 | 0.79 | CDC25A (0.61) | SMN1; SMN2RAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL14315462 | 0.79 | LTA4H (0.66) | SMN1; SMN2RAB9ANPC1SREBF2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203435-B1 | 6, 11-BRIDGED BIARYL MACROLIDES | ENANTA PHARM INC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20140187780-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130231298-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130165641-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8383785-B2 | Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8354383-B2 | 6,11-bridged biaryl macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| WO-2009137737-A2 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6, 11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009075923-A2 | 6, 11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| EP-0321115-B1 | CARBOXAMIDE DERIVATIVES HAVING TETRAZOLE AND THIAZOLE RINGS AND THEIR USE | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1991-08-14 | — | — | EP | disclosed |
| US-4946855-A | ANTIALLERGIC | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1990-08-07 | — | — | US | disclosed |
| EP-0321115-A1 | Carboxamide derivatives having tetrazole and thiazole rings and their use | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1989-06-21 | — | — | EP | disclosed |
| EP-0001727-B1 | NEW DERIVATIVES OF 4-PHENYL-2-(2',2',2-TRICHLORETHOXYCARBOXAMIDO)-THIAZOLE USEFUL AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION OF THESE COMPOUNDS | PIERRE FABRE S.A. (FR) | 1981-11-11 | — | — | EP | disclosed |
| EP-0001727-A2 | New derivatives of 4-phenyl-2-(2',2',2-trichlorethoxycarboxamido)-thiazole useful as medicaments, pharmaceutical compositions containing them and process for the preparation of these compounds | PIERRE FABRE S.A. (FR) | 1979-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165641-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | SMN1; SMN2 3161/4885RAB9A 1422/4885NPC1 96/4885 |
| US-20130231298-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | CYP8B1, SI, CYP51A1 | SMN1; SMN2 4164/4885RAB9A 157/4885NPC1 679/4885 |
| US-20140187780-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | SMN1; SMN2 3161/4885RAB9A 1422/4885NPC1 96/4885 |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | SMN1; SMN2 3004/4885RAB9A 1271/4885NPC1 90/4885 |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | CYP8B1, SI, CYP51A1 | SMN1; SMN2 4164/4885RAB9A 157/4885NPC1 679/4885 |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | SMN1; SMN2 3161/4885RAB9A 1422/4885NPC1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.